Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc CEO Forecasts Pancreatic Cancer Breakthroughs, Details PRP Trial Plans

Propanc Biopharma's CEO, James Nathanielsz, forecasts significant medical breakthroughs in pancreatic cancer treatment over the next decade, citing recent advancements from other companies in targeting KRAS mutations and using combination therapies. These developments, showing improved overall survival and one-year survival rates, highlight the need for multi-mechanism approaches due to the disease's complex biology. Propanc's lead asset, PRP, which received Orphan Drug Designation for pancreatic cancer in 2017, has shown promising compassionate use data. The company plans to file a Clinical Trial Application in Australia later this year for a Phase 1b First-In-Human study of PRP in advanced solid tumor patients, followed by two Phase 2 studies in pancreatic and ovarian cancers.

• The press release highlights recent progress in pancreatic cancer, including a late-stage trial targeting KRAS mutations that improved overall survival to approximately 13 months versus 7 months with standard treatment. Additionally, combination therapy approaches have increased one-year survival rates to about 42% compared to 22% with chemotherapy alone, underscoring the efficacy of addressing multiple biological mechanisms.
• Propanc's lead product candidate, PRP, holds Orphan Drug Designation from the USFDA for pancreatic cancer since 2017. Published compassionate use data in Scientific Reports demonstrated that a once-daily suppository of PRP (trypsinogen and chymotrypsinogen) enabled 3 out of 4 terminal pancreatic cancer patients to significantly exceed life expectancy without severe side effects.
• Propanc plans to advance PRP into further clinical trials, starting with a Phase 1b First-In-Human, Maximum Tolerated Dose study in 30-40 advanced solid tumor patients in Australia, with a Clinical Trial Application filing expected later this year. This will be followed by two Phase 2 studies, each enrolling 60 patients, to establish proof of concept for PRP in both pancreatic and ovarian cancers.

Addressing the Persistent Challenges in Pancreatic Cancer Treatment

Pancreatic cancer remains one of the most challenging malignancies to treat, with overall 5-year survival rates persisting in the single digits at approximately 8%. The disease represents the third leading cause of cancer deaths in the United States, with over 50,000 new cases annually and a similarly devastating mortality rate. Despite decades of research and therapeutic advances seen in other cancers, pancreatic adenocarcinoma continues to demonstrate exceptional resistance to conventional treatment modalities.

• Intrinsic and acquired drug resistance represents the primary obstacle to therapeutic success, with pancreatic cancer ranking among the most chemotherapy-resistant solid tumors and exhibiting the highest rates of relapse and metastasis

• Severe drug delivery barriers caused by extensive desmoplastic stroma create elevated interstitial fluid pressures, leading to vascular collapse and substantially impaired perfusion of chemotherapeutic agents to tumor sites

• Limited efficacy of standard chemotherapy regimens, including gemcitabine monotherapy and newer combinations like FOLFIRINOX and nab-paclitaxel/gemcitabine, which provide only modest survival improvements while causing significant systemic toxicity

• Immunotherapy resistance due to the inherently "immune-cold" tumor microenvironment, making pancreatic cancers largely refractory to checkpoint inhibitors that have revolutionized treatment in other malignancies

• Advanced disease presentation in most patients, with tumors deemed surgically unresectable at diagnosis, limiting treatment options primarily to systemic chemotherapy with poor outcomes

• Inadequate molecular targeting options, as current targeted therapies have failed to demonstrate clinically meaningful improvements, with only erlotinib showing modest survival benefit in combination with gemcitabine

• Complex tumor biology involving multiple dysregulated signaling pathways and epithelial-mesenchymal transition processes that contribute to chemoresistance and treatment failure

Propanc's Clinical Development Path for PRP in Advanced Cancers

Pancreatic cancer clinical trials have evolved significantly over the past two decades, with recent studies focusing on combination therapies and real-world effectiveness comparisons. The most notable recent trials include the NAPAN trial comparing second-line liposomal irinotecan combinations and the PARC study evaluating trimodal therapy approaches.

Propanc's Bold Step in Pancreatic Cancer's Evolving Landscape

The fight against pancreatic cancer has long been one of oncology's most formidable challenges. With a historically grim prognosis and limited therapeutic options, patients and clinicians alike have eagerly awaited breakthroughs. Propanc Biopharma's recent announcement regarding its lead asset, PRP, and its planned progression into Phase 1b and Phase 2 studies, signals a new wave of therapeutic exploration in this high-unmet-need area.

For decades, gemcitabine monotherapy offered only modest benefits, but the landscape is rapidly evolving. The scientific community now recognizes the necessity of multi-pronged attacks, moving towards sophisticated combination therapies and molecularly targeted agents. This shift is driven by a deeper understanding of pancreatic cancer's complex biology, including the pervasive role of KRAS mutations and the immunosuppressive tumor microenvironment. Recent successes with KRAS G12C inhibitors and the development of agents targeting KRAS G12D, such as setidegrasib and KRB-456, demonstrate the significant potential of precision oncology. Similarly, regimens like FOLFIRINOX and nab-paclitaxel plus gemcitabine have set new benchmarks for overall survival, albeit with considerable toxicity.

Propanc's strategy with PRP, which has already secured Orphan Drug Designation for pancreatic cancer, aligns with this evolving paradigm. The company aims to leverage a multi-mechanism approach, a strategy that existing evidence suggests is crucial for overcoming the disease's inherent resistance. However, the path forward is fraught with challenges:

• High attrition rates: Pancreatic cancer trials have a history of high failure, with many promising agents failing to demonstrate meaningful clinical benefit or acceptable toxicity, as seen with past attempts like 3-AP.

• Intense competition: The market is increasingly crowded with both established combination regimens and novel targeted therapies, including liposomal irinotecan for second-line treatment. PRP will need to carve out a distinct value proposition.

• Biological complexity: The disease's heterogeneity and dense stromal barrier continue to pose significant hurdles to drug delivery and efficacy, demanding robust clinical evidence.

Despite these risks, the potential for a novel agent to improve outcomes in pancreatic cancer remains immense. Propanc's expansion into ovarian cancer, another indication where combination therapies and anti-angiogenic strategies have shown promise, further underscores the company's ambition. The upcoming clinical trials for PRP will be critical in determining its place in the future treatment landscape, offering a glimmer of hope for patients facing this devastating disease.